Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19
Enanta Pharmaceuticals, Inc. (ENTA)
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.enanta.com/investor-overview
Company Research
Source: Business Wire
Company Leverages Proven Antiviral and Respiratory Expertise to Evaluate Existing Compounds and New Approaches for Treating the Novel Coronavirus Disease COVID-19 WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has initiated a program to discover direct-acting antiviral drug candidates for the treatment of patients infected with the novel coronavirus COVID-19, also known as SARS-CoV-2.The company is leveraging its years of expertise in virology, including its discovery work on two approved protease inhibitors – paritaprevir and glecaprevir – for use against hepatitis C virus (HCV), its development of a candidate for hepatitis B virus (HBV), and most importantly, its development of candidates for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), to explore approaches against this pandemic h
Show less
Read more
Impact Snapshot
Event Time:
ENTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENTA alerts
High impacting Enanta Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ENTA
News
- The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.MarketBeat
- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $22.00 price target on the stock.MarketBeat
- Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $22.00 price target on the stock.MarketBeat
ENTA
Earnings
- 8/5/24 - Beat
ENTA
Sec Filings
- 11/14/24 - Form SC
- 10/17/24 - Form SC
- ENTA's page on the SEC website